TTrialPathMatch Me to Trials
← Back to trials
RecruitingPancreatic CancerColorectal CancerHepatocellular Carcinoma

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

Eligible age

18–99 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.

Sponsor: University of Arizona

You may qualify if…

  • ✓ Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below.
  • ✓ The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
  • ✓ Measurable disease per RECIST v1.1 as determined by the investigator
  • ✓ Patients must be appropriate candidates for first-line, SOC treatment.
  • ✓ SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:
  • ✓ Colorectal: FOLFOX or FOLIFIRI +/- bevacizumab
  • ✓ Pancreatic: mFOLFIRINOX
  • ✓ HCC: Tremelimumab/Durvalumab

You may not qualify if…

  • ✕ The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease.
  • ✕ BMI \< 25 kg/m2
  • ✕ For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.
  • ✕ For colorectal cancer only - BRAF V600E mutant tumors.
  • ✕ A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  • ✕ A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®.
  • ✕ Cachexia
  • ✕ Subjects on insulin.

Where it's recruiting

Arizona

Tucson

Source: ClinicalTrials.gov · NCT07627191 · last updated 2026-11-16

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colo · TrialPath